News Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
8.7 ^USD	-6.05%		-16.10%	+41.69%

Apr. 01	Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	MT
Apr. 01	Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	AQ
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	Apr. 01	MT
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	Apr. 01	DJ
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	Apr. 01	AQ
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	Apr. 01	CI
William Blair Starts Solid Biosciences With Outperform Rating	Mar. 28	MT
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	Mar. 27	AQ
Barclays Adjusts Price Target on Solid Biosciences to $21 From $8, Maintains Overweight Rating	Mar. 18	MT
Citigroup Starts Coverage on Solid Biosciences With Buy Rating, $16 Price Target	Mar. 15	MT
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Piper Sandler Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $20 From $8	Mar. 14	MT
Transcript : Solid Biosciences Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	Mar. 13
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	Mar. 13	AQ
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
HC Wainwright Adjusts Solid Biosciences' PT to $16 From $9, Maintains Buy Rating	Mar. 11	MT
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	Mar. 07	AQ
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd	Mar. 07	CI
Solid Biosciences to Participate at Upcoming Investor Conferences	Mar. 06	AQ
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate	Jan. 16	MT
Solid Biosciences Gets Orphan Drug Designation for SGT-003	Jan. 16	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Summary

Filters